Teva Pharmaceutical (TEVA) Tops Q2 EPS by 2c; Boosts FY14 EPS Outlook

Teva Pharmaceutical (NYSE: TEVA) reported Q2 EPS of $1.23, $0.02 better than the analyst estimate of $1.21. Revenue for the quarter came in at $5 billion versus the consensus estimate of $5.08 billion.

EPS guidance for 2014 improved to $4.90-5.10 in the exclusive Copaxone scenario, and to $4.50-4.80 in the generic Copaxone® scenario. The consensus is at $4.82.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Southern First Bancshares, Inc. (SFST) Misses Q1 EPS by 8c
• Oceanfirst Financial (OCFC) Tops Q1 EPS by 3c